Recently published in Cell, using genetic engineering to inactivate the CD33 gene of HSCs can avoid the toxic effect of CD33 CART on bone marrow, thus making it possible for CD33 CART to treat AML (114). The gene discussed is CD33; the disease is acute myeloid leukemia.